References and Notes
1a
Luzzio FA.
Piatt Zachert D.
Tetrahedron Lett.
1998,
39:
2285
1b
Campbell JB.
Dedinas RF.
Trumbower-Walsh SA.
J. Org. Chem.
1996,
61:
6205
1c
Decroix B.
Pigeon P.
. Tetrahedron Lett.
1996,
37:
7707
1d
Decroix B.
Pigeon P.
Othman M.
Tetrahedron
1997,
53:
2495
1e
Allin SM.
Northfield CJ.
Page MI.
Slawin AMZ.
Tetrahedron Lett.
1997,
38:
3627
1f
Kundu NG.
Khan MW.
Tetrahedron Lett.
1997,
38:
6937
1g
Kitching MS.
Clegg W.
Elsewood MRJ.
Griffin RJ.
Golding BT.
Synlett
1999,
997
2a
Nannin G.
Griraldi PN.
Molgora G.
Biasoli G.
Spinelli F.
Logemann L.
Dradi E.
Zanni G.
Buttinoni A.
Tommasini R.
Arzneim. Forsch.
1973,
23:
1090
2b Hisamitsu Pharmaceutical Co., Inc. Japan Kokai Tokyo Koho 149257, 1980; Chem. Abstr. 1981, 94, 174879; address: P. J. Kocienski, School of Chemistry, Univerity of Leeds, Leeds LS2 9JT, UK.
3
Schmahl H.-J.
Denker L.
Plum C.
Chahoud I.
Nau H.
Arch. Toxicol.
1996,
11:
749
4
Plowman J.
Paull KD.
Atassi G.
Harrison S.
Dykes D.
Kabbe N.
Narayan VL.
Yoder O.
Invest. New Drugs
1988,
6:
147
5a
Ganesan A.
Wang H.
Tetrahedron Lett.
1998,
39:
9097
5b
Anzani M.
Capelli A.
Vomero S.
Heterocycles
1994,
38:
103
6
Horii Z.
Iwata C.
Tamura Y.
J. Org. Chem.
1961,
26:
2273
7
Orito K.
Horibata A.
Nakamura T.
Ushito H.
Nagasaki H.
Yuguchi M.
Yamashita S.
Tokuda M.
J. Am. Chem. Soc.
2004,
126:
14342
8
Hoarau C.
Couture A.
Deniau E.
Grandclaudon P.
Synthesis
2000,
655
9a
Späth E.
Lintner J.
Ber. Dtsch. Chem. Ges. B
1936,
69:
2727
9b
Barrios I.
Camps P.
Comes-Franchini M.
Muñoz-Torrero D.
Ricci A.
Sánchez L.
Tetrahedron
2003,
59:
1971
10 See for mechanical study: Decker M.
Nguyen TTH.
Lehmann J.
Tetrahedron
2004,
60:
4567
11
Lesimple P.
Bigg DCH.
Synthesis
1991,
306
12 See ref. 6 for preparation of 6i.
13
Kornblum N.
Smiley RA.
Blackwood RK.
Iffland DC.
J. Am. Chem. Soc.
1955,
77:
6269
14 When 1 equiv of Grignard reagent was employed, O-protected compound 8 was obtained predominantly in entry 5.
15
Typical Experimental Procedure.
To a three-necked 50-mL round-bottomed flask equipped with dropping funnel were charged DMI (15 mL) and o-hydroxymethylbenzamide 6a (1.35 g, 5.00 mmol). The resulting solution was cooled to 0 °C, and then 1.98 M of i-PrMgCl-THF (5.63 mL, 11.15 mol, 2.23 equiv to 6a) was added dropwise. The resulting solution was warmed to ambient temperature and stirred for 0.5 h. The solution was cooled to 0 °C, and then ClP(O)(NMe2)2 (0.94 mL, 6.50 mmol, 1.3 equiv to 6a) was added dropwise. The mixture was warmed to ambient temperature, and stirred for 14 h. The resulting solution was quenched by 2 N aq HCl (10 mL). The mixture was extracted with i-PrOAc (3 × 10 mL), and the combined i-PrOAc extracts were washed with H2O (2 × 10 mL) and dried over anhyd Na2SO4. Removal of the solvent and subsequent silica gel chromatography (heptane and EtOAc) afforded the corresponding lactam 1a in a pure form.
16
Spectroscopic Data for New Compounds.
Compound 6c: IR (neat): 1673, 1608, 1510, 1451, 1411, 1356, 1308, 1274, 1242, 1175, 1033, 1007, 837, 813, 768, 673 cm-1. 1H NMR (300 MHz, CDCl3): δ = 3.79 (s, 3 H), 4.22 (s, 2 H), 4.72 (s, 2 H), 6.86 (d, J = 8.5 Hz, 2 H), 7.24 (d, J = 8.5 Hz, 2 H), 7.53 (s, 1 H), 7.60 (d, J = 8.1 Hz, 1 H), 7.74 (d, J = 8.1 Hz, 1 H). 13C NMR (CDCl3): δ = 45.82, 48.77, 55.27, 114.18, 125.21, 125.93, 126.12, 128.75, 129.50, 131.47, 131.72, 142.97, 159.21, 167.38.
Compound 6f: IR (neat): 1658, 1460, 1409, 1367, 1303, 1234, 1057, 764, 737, 686 cm-1. 1H NMR (300 MHz, CDCl3): δ = 4.86 (s, 2 H), 7.18-7.21 (m, 1 H), 7.41-7.46 (m, 2 H), 7.48-7.53 (m, 2 H), 7.58-7.60 (m, 1 H), 7.86-7.89 (m, 2 H), 7.92-7.94 (m, 1 H). 13C NMR (CDCl3): δ = 50.71, 119.46, 122.59, 124.15, 124.46, 128.37, 129.14, 132.05, 133.24, 139.50, 140.09, 167.49.
Compound 6g: IR (neat): 2227, 1677, 1610, 1447, 1409, 1230, 1060, 877, 839, 770, 677 cm-1. 1H NMR (300 MHz, CDCl3): δ = 1.32 (d, J = 6.8 Hz, 6 H), 4.41 (s, 2 H), 4.69 (sept, J = 6.8 Hz, 1 H), 7.76 (d, J = 8.2 Hz, 1 H), 7.77 (s, 1 H), 7.94 (d, J = 8.2 Hz, 1 H). 13C NMR (CDCl3): δ = 20.75, 43.12, 44.90, 114.56, 118.31, 124.45, 126.75, 132.09, 137.32, 141.51, 165.88.